Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy
April 22, 2024 16:32 ET
|
Ring Therapeutics
Development of a new class of viral vectors – Anellovectors – with potential to deliver DNA payloads across broad tissue types in redosable manner Anellovectors demonstrate expanded payload capacity...
Ring Therapeutics Publishes a Novel Gene Delivery Platform Based on the Commensal Human Anellovirus
April 01, 2024 08:00 ET
|
Ring Therapeutics
– Publication describes the first gene delivery vector system based on a human commensal virus, the anellovirus – – Development of the Self-Amplifying Trans-complementation of a Universal Recombinant...
Ring Therapeutics Presents New Data on Anellogy™ Platform at the 30th Annual European Society of Gene & Cell Therapy Congress
October 24, 2023 08:00 ET
|
Ring Therapeutics
Translation of innate properties of anelloviruses to create Anellovectors with strengthened tropism and immune stealth, enabling redosability Transduction and expression across a variety of tissues...
Ring Therapeutics Announces Two Late Breaker Presentations at the 30th Annual European Society of Gene & Cell Therapy Conference
September 26, 2023 08:00 ET
|
Ring Therapeutics
Ring to present new data on its Anellogy™ platform The first new class of viral vector in decades - Robust transduction of a variety of cell and tissue types achieved by AnelloVectors Development of...
Ring Therapeutics Announces Appointment of Bioprocess and Biomanufacturing Veteran Konstantin Konstantinov, Ph.D. as Chief Technology Officer
June 07, 2023 08:00 ET
|
Ring Therapeutics
CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today...
Ring Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategy
May 01, 2023 08:00 ET
|
Ring Therapeutics
McNulty brings deep experience in capital formation and business development to Ring Follows recent appointment of Dr. Christopher Wright as Chief Medical Officer CAMBRIDGE, Mass., May 01, 2023 ...
Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines
March 09, 2023 06:30 ET
|
Ring Therapeutics
– Ring raised a total of $86.5 million from new and returning investors, validating its unique approach to creating next-generation programable genetic medicines – – The proceeds from this raise will...
Ring Therapeutics Announces Appointment of Industry Veteran Christopher Wright, M.D., Ph.D. as Chief Medical Officer, Head of Translational Research
January 30, 2023 08:00 ET
|
Ring Therapeutics
CAMBRIDGE, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today...
Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector™ Compositions
September 20, 2022 08:00 ET
|
Ring Therapeutics
CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today...
Ring Therapeutics Announces Three Presentations at the 41st Annual Meeting of the American Society for Virology (ASV)
July 18, 2022 08:00 ET
|
Ring Therapeutics
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today...